TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9128316

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg taken late in the evening, coupled with clarithromycin 250 mg b.i.d. and metronidazole 500 mg b.i.d. for the first 2 weeks.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg taken before breakfast, coupled with clarithromycin 250 mg b.i.d. and metronidazole 500 mg b.i.d. for the first 2 weeks.
Number of subjects: 80
Study: 8831524

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A) injected bilaterally into the external sphincter or puborectalis muscle (6 to 15 units)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A)
Number of subjects: 4
Study: 2675434

Group type: EXPERIMENTAL
Intervention: 5 mg nitrazepam
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 1 mg lorazepam
Number of subjects: 46
Study: 1088951

Group type: EXPERIMENTAL
Intervention: Haloperidol (1.0 mg, intramuscular injection)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 28
Study: 30843092

Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon (PCB) angioplasty
Number of subjects: 369

Group type: COMPARATOR
Intervention: Angioplasty without paclitaxel (control group)
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Both groups (PCB and control)
Number of subjects: 369
Study: 29916231

Group type: EXPERIMENTAL
Intervention: Early amniotomy (performed when patients entered the active phase of labor, cervical dilatation 3‐5 cm, n=60)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Late amniotomy (membrane left intact, amniotomy reserved for specific indications, n=60)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Early amniotomy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Late amniotomy
Number of subjects: 120
Study: 26323726

Group type: EXPERIMENTAL
Intervention: Jaw trust with open mouth
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Jaw trust with teeth prottution
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Head tilt chin lift
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Triple airway maneuvers
Number of subjects: 121
Study: 23793449

Group type: EXPERIMENTAL
Intervention: Isoflurane anesthesia (n=16)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Propofol anesthesia (n=18)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Comparison between isoflurane and propofol
Number of subjects: 34
Study: 21464195

Group type: EXPERIMENTAL
Intervention: 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine (Focetria) administered in 2 doses (dose 1 at enrollment and dose 2 after 4 weeks)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine (Focetria)
Number of subjects: 105
Study: 19542766

Group type: EXPERIMENTAL
Intervention: Long-term intake of 'benifuuki' green tea (34 mg O-methylated catechin per day for 1.5 months before pollen exposure)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Long-term intake of 'benifuuki' green tea
Number of subjects: 38

Group type: COMPARATOR
Intervention: Short-term intake of 'benifuuki' green tea
Number of subjects: 38
Study: 16731323

Group type: EXPERIMENTAL
Intervention: Fentanyl (10 mug bolus, n = 17)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tramadol (20 mg bolus, n = 13)
Number of subjects: 30
Study: 15217524

Group type: EXPERIMENTAL
Intervention: greens+
Number of subjects: 105

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 105
Study: 11751182

Group type: EXPERIMENTAL
Intervention: Budesonide (400 microg twice daily)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Air (control)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Ozone exposure (0.27 ppm)
Number of subjects: 11
Study: 9656405

Group type: EXPERIMENTAL
Intervention: Ofloxacin containing combined drug regimens
Number of subjects: 60

Group type: COMPARATOR
Intervention: Rifampicin
Number of subjects: 60
Study: 8480265

Group type: EXPERIMENTAL
Intervention: Resectoscope (group 1)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Microscissors (group 2)
Number of subjects: 23
Study: 3168500

Group type: EXPERIMENTAL
Intervention: Oral nonabsorbable antimicrobial agents (tobramycin, amphotericin B, polymyxin E) in addition to parenteral antibiotics
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (no nonabsorbable antimicrobial agents)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Oral nonabsorbable antimicrobial agents
Number of subjects: 96
Study: 30307504

Group type: EXPERIMENTAL
Intervention: 24-h urine samples
Number of subjects: 3270

Group type: EXPERIMENTAL
Intervention: Spot urine estimates using individual concentrations and standard urine volume
Number of subjects: 3270

Group type: COMPARATOR
Intervention: Tanaka equation
Number of subjects: 3270

Group type: COMPARATOR
Intervention: Kawasaki equation
Number of subjects: 3270

Group type: COMPARATOR
Intervention: Intersalt without potassium equation
Number of subjects: 3270

Group type: COMPARATOR
Intervention: Intersalt with potassium equation
Number of subjects: 3270
Study: 28302636

Group type: EXPERIMENTAL
Intervention: MR within 24 hours of admission and at discharge
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 200
Study: 25352018

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 1778

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 1778

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1778
Study: 22290216

Group type: EXPERIMENTAL
Intervention: Side-to-side anastomosis
Number of subjects: 67

Group type: COMPARATOR
Intervention: End-to-end anastomosis
Number of subjects: 67
Study: 21592480

Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg/day for 4 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 20
Study: 18089691

Group type: EXPERIMENTAL
Intervention: 1000 IU vitamin D2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1000 IU vitamin D3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 500 IU vitamin D2 plus 500 IU vitamin D3
Number of subjects: 0
Study: 16565456

Group type: EXPERIMENTAL
Intervention: Simple Dissemination (SD)
Number of subjects: 5849

Group type: EXPERIMENTAL
Intervention: Intensive Dissemination (ID)
Number of subjects: 5849

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 5849
Study: 14582689

Group type: EXPERIMENTAL
Intervention: Monochromatic pulsating light treatment
Number of subjects: 164

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 164
Study: 11078237

Group type: COMPARATOR
Intervention: Fenofibrate 200 mg
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg plus Fenofibrate 200 mg
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg plus Fenofibrate 200 mg
Number of subjects: 102
Study: 8969977

Group type: EXPERIMENTAL
Intervention: FK506 (tacrolimus)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Therapeutic monitoring of whole-blood FK506 levels
Number of subjects: 0
Study: 1428034

Group type: EXPERIMENTAL
Intervention: Endoscopic sclerotherapy (EST)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 32
Study: 6366553

Group type: COMPARATOR
Intervention: Moderate alcohol intake (control drinking group)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Abstention from alcohol (abstention group)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Resumption of drinking after abstention
Number of subjects: 24
Study: 31561881

Group type: EXPERIMENTAL
Intervention: Sevoflurane at 0.5 MAC
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sevoflurane at 1.0 MAC
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sevoflurane at 1.5 MAC
Number of subjects: 60
Study: 29381726

Group type: EXPERIMENTAL
Intervention: Modified Valsalva maneuver (MVM) for 30 days
Number of subjects: 72

Group type: COMPARATOR
Intervention: Conventional treatment (NVM group)
Number of subjects: 72
Study: 26771282

Group type: EXPERIMENTAL
Intervention: Food supplement containing forskolin, homotaurine, carnosine, folic acid, vitamins B1, B2, B6, and magnesium, 2 tablets per day for 12 months.
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control treatment (not specified in detail).
Number of subjects: 22
Study: 24631567

Group type: EXPERIMENTAL
Intervention: tDCS alone
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: MP alone
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Combination of tDCS and MP
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 9
Study: 22271411

Group type: EXPERIMENTAL
Intervention: Colesevelam 1.875 g b.i.d. for 14 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 24
Study: 20306005

Group type: EXPERIMENTAL
Intervention: Intensive vascular care (4-monthly visits to a practice nurse monitoring cardiovascular risk factors)
Number of subjects: 3535

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 3535

Group type: EXPERIMENTAL
Intervention: Intensive vascular care
Number of subjects: 3535
Study: 18925641

Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (1 patient withdrew consent at 3 months)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Combination HBIG plus lamivudine
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Combination adefovir/lamivudine prophylaxis
Number of subjects: 34

Group type: COMPARATOR
Intervention: IM HBIG/lamivudine
Number of subjects: 34
Study: 16208659

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 11863090

Group type: EXPERIMENTAL
Intervention: Paclitaxel plus carboplatin (PC) - P 175 mg/m2 and C at AUC = 7, intravenous infusion on day 1
Number of subjects: 90

Group type: COMPARATOR
Intervention: Paclitaxel plus gemcitabine (PG) - P 175 mg/m2 on day 1 and G 1000 mg/m2 on days 1 and 8, every 3 weeks
Number of subjects: 90
Study: 10079631

Group type: EXPERIMENTAL
Intervention: Digora phosphor plate
Number of subjects: 130

Group type: COMPARATOR
Intervention: Trophy RVG XL, CCD-based sensor
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Both systems
Number of subjects: 130
Study: 7572513

Group type: EXPERIMENTAL
Intervention: 5 ml gadopentetate dimeglumine
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: 10 ml gadopentetate dimeglumine
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: 20 ml gadopentetate dimeglumine
Number of subjects: 152

Group type: COMPARATOR
Intervention: Unenhanced MR angiograms
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced MR angiograms
Number of subjects: 152
Study: 2251208

Group type: EXPERIMENTAL
Intervention: Yohimbine (15 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 7011019

Group type: EXPERIMENTAL
Intervention: Twice daily applications of a povidone-iodine solution and ointment
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Once daily meatal cleansing with a nonantiseptic solution of green soap and water
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no treatment) for povidone-iodine
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no special meatal care) for green soap
Number of subjects: 200
Study: 31240335

Group type: EXPERIMENTAL
Intervention: Dermaplasty-assisted lipoplasty (DAL)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Standard suction-assisted lipectomy (SAL)
Number of subjects: 135
Study: 31079535

Group type: EXPERIMENTAL
Intervention: Pegloticase (8 mg every 2 weeks)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study: 28962046

Group type: EXPERIMENTAL
Intervention: Sodium butyrate capsules
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Inulin supplement powder
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sodium butyrate + inulin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 25040503

Group type: EXPERIMENTAL
Intervention: PCC/PGL patients
Number of subjects: 28
Study: 23567394

Group type: EXPERIMENTAL
Intervention: Psychotherapy for 12 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Psychotherapy nonresponders
Number of subjects: 22
Study: 21354553

Group type: EXPERIMENTAL
Intervention: TRACEr-RAV1
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: TRACEr-RAV2
Number of subjects: 36

Group type: COMPARATOR
Intervention: TRACEr-Rail
Number of subjects: 36
Study: 19683825

Group type: EXPERIMENTAL
Intervention: Bed-time NPH insulin
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 28
Study: 17846285

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (600 IU on alternate days)
Number of subjects: 39876

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39876
Study: 15281501

Group type: EXPERIMENTAL
Intervention: Bupivacaine (0.125%; 0.2 mg x kg(‐1) x h(‐1))
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Levobupivacaine (0.125%; 0.2 mg x kg(‐1) x h(‐1))
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Ropivacaine (0.125%; 0.2 mg x kg(‐1) x h(‐1))
Number of subjects: 81

Group type: COMPARATOR
Intervention: All groups (Bupivacaine, Levobupivacaine, Ropivacaine)
Number of subjects: 81
Study: 11157017

Group type: EXPERIMENTAL
Intervention: Thermography catheter method to detect temperature differences (Delta T) between solid tumors and normal areas.
Number of subjects: 20
Study: 9990415

Group type: EXPERIMENTAL
Intervention: Adapalene 0.1% gel
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Adapalene 0.1% cream
Number of subjects: 30

Group type: COMPARATOR
Intervention: Tretinoin 0.05% cream
Number of subjects: 30

Group type: COMPARATOR
Intervention: Tretinoin 0.1% cream
Number of subjects: 30

Group type: COMPARATOR
Intervention: Tretinoin formulations (0.05% and 0.1%)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Adapalene 0.1% gel and cream
Number of subjects: 30
Study: 7921299

Group type: EXPERIMENTAL
Intervention: Letter addressed to parents (parent group)
Number of subjects: 449

Group type: COMPARATOR
Intervention: Letter addressed to adolescents (adolescent group)
Number of subjects: 449
Study: 3415207

Group type: EXPERIMENTAL
Intervention: Moxalactam (2 g i.v. every 8 h for 5 doses, then 2 g every 12 h)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Clindamycin (600 mg i.v. every 6 h) plus Gentamicin (1.5 mg/kg i.v. every 8 h)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Clindamycin plus Gentamicin
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Moxalactam
Number of subjects: 114
Study: 29895093

Group type: EXPERIMENTAL
Intervention: Virtual Refractor simulator
Number of subjects: 24

Group type: COMPARATOR
Intervention: Non-intervention group
Number of subjects: 24
Study: 27703346

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid (ICS)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 25215556

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (Z6, n = 616)
Number of subjects: 1233

Group type: COMPARATOR
Intervention: Placebo infusions (Z3P3, n = 617)
Number of subjects: 1233

Group type: EXPERIMENTAL
Intervention: Discontinuation of treatment after 3 years
Number of subjects: 1233
Study: 23590327

Group type: EXPERIMENTAL
Intervention: C-Mill gait adaptability treadmill training (high-intensity, adaptive stepping)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Conventional treadmill training (high-intensity, repetitive stepping)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Usual care physical therapy
Number of subjects: 126
Study: 20044162

Group type: EXPERIMENTAL
Intervention: Telemedicine system based on Internet and short message service
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 20031551

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Pravastatin 10 mg
Number of subjects: 509
Study: 18154091

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil administration during skin plasty operation
Number of subjects: 61
Study: 12940804

Group type: EXPERIMENTAL
Intervention: Fixed combination of indomethacin, prochlorperazine, and caffeine
Number of subjects: 112

Group type: COMPARATOR
Intervention: Sumatriptan
Number of subjects: 112
Study: 10613779

Group type: EXPERIMENTAL
Intervention: Antibiotic treatments
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Various therapies
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Future RCTs
Number of subjects: 506
Study: 9327254

Group type: EXPERIMENTAL
Intervention: Behavioral medicine intervention (6-week duration)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 82
Study: 8447130

Group type: EXPERIMENTAL
Intervention: Drainage
Number of subjects: 80

Group type: COMPARATOR
Intervention: Nondrainage
Number of subjects: 80
Study: 3468098

Group type: EXPERIMENTAL
Intervention: 400 mg ofloxacin by mouth once daily for ten days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 400 mg ofloxacin by mouth twice daily for ten days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Concomitantly administered theophylline
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 400 mg ofloxacin
Number of subjects: 30
Study: 31606860

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group for HIIT
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group for MICT
Number of subjects: 44
Study: 29368594

Group type: EXPERIMENTAL
Intervention: Propofol and dexmedetomidine
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Sevoflurane and dexmedetomidine
Number of subjects: 84

Group type: COMPARATOR
Intervention: Propofol and normal saline
Number of subjects: 84

Group type: COMPARATOR
Intervention: Sevoflurane and normal saline
Number of subjects: 84
Study: 27234663

Group type: EXPERIMENTAL
Intervention: Weekly PST (n=1465)
Number of subjects: 2922

Group type: COMPARATOR
Intervention: Monthly HQACM (n=1457)
Number of subjects: 2922

Group type: EXPERIMENTAL
Intervention: PST twice weekly (n=118)
Number of subjects: 2922

Group type: EXPERIMENTAL
Intervention: PST once every 4 weeks (n=116)
Number of subjects: 2922
Study: 24295613

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine with 70% alcohol swab sticks for exit-site care and 70% alcohol pads for 'scrub the hubs' in dialysis-related CVC care procedures
Number of subjects: 211

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 211
Study: 22004055

Group type: EXPERIMENTAL
Intervention: Access to CHESS (Comprehensive Health Enhancement Support System)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Internet access to high-quality lung cancer websites
Number of subjects: 246
Study: 20464815

Group type: EXPERIMENTAL
Intervention: Continuous altitude changes in +3 Gz
Number of subjects: 2

Group type: COMPARATOR
Intervention: Continuous altitude changes in +1 Gz
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Stroop task in +3 Gz
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Dual-task costs
Number of subjects: 2
Study: 18514326

Group type: EXPERIMENTAL
Intervention: Remitted substance use disorders (SUDs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No remitted substance use disorders (SUDs)
Number of subjects: 0
Study: 16279133

Group type: EXPERIMENTAL
Intervention: Active management practices
Number of subjects: 231

Group type: COMPARATOR
Intervention: Traditional management practices
Number of subjects: 231
Study: 14682413

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 400 microg once daily
Number of subjects: 74

Group type: COMPARATOR
Intervention: Oral montelukast 10 mg once daily
Number of subjects: 74

Group type: COMPARATOR
Intervention: Sustained-release theophylline 400 mg once daily
Number of subjects: 74
Study: 10028204

Group type: EXPERIMENTAL
Intervention: Imaginal Exposure (IE)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 72
Study: 8897759

Group type: EXPERIMENTAL
Intervention: 10 million units of IFN-alpha 2b daily for 2 weeks
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 10 million units of IFN-alpha 2b twice a week for 24 weeks
Number of subjects: 71
Study: 1516983

Group type: EXPERIMENTAL
Intervention: Embolization of the internal spermatic vein (51 men)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Ivanissevich technique of high ligation of the spermatic veins (43 men)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Bernardi technique of high ligation (43 men)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Control group (Bernardi technique)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Control group (Ivanissevich technique)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Control group (Embolization)
Number of subjects: 137
Study: 6334456

Group type: EXPERIMENTAL
Intervention: Humidified heated inspired gases at 45 degrees C
Number of subjects: 30

Group type: COMPARATOR
Intervention: Dry gases at room temperature
Number of subjects: 30
Study: 31794566

Group type: EXPERIMENTAL
Intervention: Art Therapy (AT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting List (WL)
Number of subjects: 0
Study: 30134299

Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise (0-12 weeks)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: High-intensity exercise (13-24 weeks)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Moderate-intensity exercise (13-24 weeks)
Number of subjects: 59
Study: 26356548

Group type: EXPERIMENTAL
Intervention: RPA training (leg-press exercise, twice a week for 6 weeks, 1 or 2 blocks of 5 sets × 5 repetitions with 20 s of passive recovery between sets and 3 min between blocks)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study: 25349310

Group type: EXPERIMENTAL
Intervention: Fetal Alcohol Syndrome (FAS)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Partial Fetal Alcohol Syndrome (PFAS)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Alcohol-related neurodevelopmental disorder (ARND)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: FASD (Fetal Alcohol Spectrum Disorders)
Number of subjects: 70

Group type: COMPARATOR
Intervention: FAS
Number of subjects: 70

Group type: COMPARATOR
Intervention: PFAS
Number of subjects: 70

Group type: COMPARATOR
Intervention: Total FASD
Number of subjects: 70